- Public Comps
- Graphy
Graphy Valuation Multiples
Discover revenue and EBITDA valuation multiples for Graphy and similar public comparables like MaxCyte, 6K Additive, Aroa Biosurgery, EKF Diagnostics and more.
Graphy Overview
About Graphy
Graphy Inc is engaged in developing customized materials (3D printing materials) based on oligomer synthesis technology, photo-curable resins and materials for 3D printing in the dental industry. Its products include Shape Memory Aligner, Permanent C&B, Denture Base, Mouth Guard, and others.
Founded
2017
HQ

Employees
N/A
Website
Financials (LTM)
EV
$151M
Valuation Multiples
Start free trialGraphy Financials
Graphy reported last 12-month revenue of $21M and negative EBITDA of ($2M).
In the same LTM period, Graphy generated $15M in gross profit, ($2M) in EBITDA losses, and had net loss of ($3M).
Graphy P&L
In the most recent fiscal year, Graphy reported revenue of $14M and EBITDA of ($7M).
Graphy is unprofitable as of last fiscal year, with gross margin of 60%, EBITDA margin of (48%), and net margin of (57%).
Financial data powered by Morningstar, Inc.
Graphy Stock Performance
Graphy has current market cap of $147M, and enterprise value of $151M.
Graphy's stock price is $13.24.
Graphy has an EPS (earnings per share) of $-0.74.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $151M | $147M | -4.1% | - | - | - | $-0.74 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGraphy Valuation Multiples
Graphy trades at 7.2x EV/Revenue multiple, and (80.0x) EV/EBITDA.
Graphy Financial Valuation Multiples
As of August 14, 2026, Graphy has market cap of $147M and EV of $151M.
Graphy has a P/E ratio of (47.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Graphy Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Graphy Margins & Growth Rates
Graphy grew revenue by 72% but EBITDA decreased by 118% in the last fiscal year.
In the most recent fiscal year, Graphy reported gross margin of 60%, EBITDA margin of (48%), and net margin of (57%).
Graphy Margins
Graphy Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Graphy Operational KPIs
Graphy's Rule of 40 is 78% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Graphy's Rule of X is 186% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Graphy Competitors
Graphy competitors include MaxCyte, 6K Additive, Aroa Biosurgery, EKF Diagnostics, Humacyte, Inogen, AOTI, Quanterix, Sisram Medical and EBR Systems.
Most Graphy public comparables operate across 3D Printing, Medical Devices, DeepTech, Industry 4.0 and BioTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 1.8x | 1.9x | (1.5x) | (1.9x) | |||
| 6.6x | 5.2x | (9.1x) | (15.4x) | |||
| 2.2x | 2.1x | 19.1x | 18.9x | |||
| 1.9x | 1.9x | 7.9x | 7.6x | |||
| 68.3x | 42.8x | (6.3x) | - | |||
| 0.2x | 0.2x | (6.8x) | 18.5x | |||
| 2.2x | 2.1x | 19.5x | 20.8x | |||
| 0.5x | 0.5x | (0.8x) | (1.2x) | |||
This data is available for Pro users. Sign up to see all Graphy competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Graphy
| When was Graphy founded? | Graphy was founded in 2017. |
| Where is Graphy headquartered? | Graphy is headquartered in South Korea. |
| Is Graphy publicly listed? | Yes, Graphy is a public company listed on Korea Exchange. |
| What is the stock symbol of Graphy? | Graphy trades under 318060 ticker. |
| When did Graphy go public? | Graphy went public in 2025. |
| Who are competitors of Graphy? | Graphy main competitors include MaxCyte, 6K Additive, Aroa Biosurgery, EKF Diagnostics, Humacyte, Inogen, AOTI, Quanterix, Sisram Medical, EBR Systems. |
| What is the current market cap of Graphy? | Graphy's current market cap is $147M. |
| What is the current revenue of Graphy? | Graphy's last 12 months revenue is $21M. |
| What is the current revenue growth of Graphy? | Graphy revenue growth (NTM/LTM) is 44%. |
| What is the current EV/Revenue multiple of Graphy? | Current revenue multiple of Graphy is 7.2x. |
| Is Graphy profitable? | No, Graphy is not profitable. |
| What is the current EBITDA of Graphy? | Graphy has negative EBITDA and is not profitable. |
| What is Graphy's EBITDA margin? | Graphy's last 12 months EBITDA margin is (9%). |
| What is the current EV/EBITDA multiple of Graphy? | Current EBITDA multiple of Graphy is (80.0x). |
| What is the current FCF of Graphy? | Graphy's last 12 months FCF is ($8M). |
| What is Graphy's FCF margin? | Graphy's last 12 months FCF margin is (36%). |
| What is the current EV/FCF multiple of Graphy? | Current FCF multiple of Graphy is (19.9x). |
| How many companies Graphy has acquired to date? | Graphy hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Graphy has invested to date? | Graphy hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Graphy
Lists including Graphy
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




